NSE: AUROPHARMA · 5 November 2026
AUROBINDO PHARMA LTD F&O Intelligence
Data-mining view of cash participation, delivery, futures activity, open interest and recent positioning.
Last 3 Sessions: Cash Activity & Delivery
| Date | Cash Volume | Number of Trades | Shares Traded per Trade | Delivery % | Close / Change |
|---|---|---|---|---|---|
| 03 Nov | 13.23 L shares | 58,020 | 22.8 WittyTrades Proprietary |
59.64% | Rs 1,694.50 (+0.64%) |
| 04 Nov | 21.39 L shares | 83,445 | 25.6 WittyTrades Proprietary |
62.65% | Rs 1,705.00 (+0.62%) |
| 05 Nov | 30.99 L shares | 109,754 | 28.2 WittyTrades Proprietary |
34.68% | Rs 1,785.00 (+4.69%) |
Average number of shares traded per trade was 28.2 in the latest session versus a 25.6 3-session average. The latest average trade size was close to its 3-session baseline rather than showing a clear larger-ticket surge. Latest delivery was 34.7% versus a 3-session average of 52.3%.
Last 3 Sessions: Futures vs Cash Participation
| Date | Near Future / Change | Futures Volume (Shares) | Cash Volume (Shares) | F&O/Cash Participation Ratio | Aggregate Futures OI | Positioning Read |
|---|---|---|---|---|---|---|
| 03 Nov | Rs 1,691.50 (+0.71%) | 13.14 L shares | 13.23 L shares | 0.99x WittyTrades Proprietary |
1.42 Cr shares (—) | Positioning unavailable |
| 04 Nov | Rs 1,710.50 (+1.12%) | 28.87 L shares | 21.39 L shares | 1.35x WittyTrades Proprietary |
1.46 Cr shares (+2.64%) | Long buildup |
| 05 Nov | Rs 1,779.80 (+4.05%) | 51.27 L shares | 30.99 L shares | 1.65x WittyTrades Proprietary |
1.43 Cr shares (-1.82%) | Short covering |
How open interest shifted across expiries
| Expiry | Latest OI | 1-Day OI Change |
|---|---|---|
| 23 Nov | 1.41 Cr shares | -3.01 L |
| 29 Dec | 1.64 L shares | +27,500 |
| 25 Jan | 20,350 shares | +9,350 |
The front expiry lost OI while later expiries gained OI, confirming contract migration. About 1.3% of aggregate OI sat beyond the front expiry. This is an expiry-structure observation, not a directional signal by itself.
- Whether aggregate futures OI expands or contracts alongside the next price move.
- Whether the WittyTrades F&O/Cash Participation Ratio remains elevated or normalises.
- Whether Shares Traded per Trade moves materially above or below its recent baseline.
- Whether delivery participation holds above or below the recent 3-session average of 52.3%.
- Whether later-expiry OI continues to absorb positions from the front contract as expiry approaches.
Higher Shares Traded per Trade can flag larger-ticket participation, but exchange trade-count data does not identify the buyer or seller category. The F&O/Cash Participation Ratio measures participation intensity and does not by itself distinguish directional trading, hedging or arbitrage.
- Aurobindo Pharma Limited shares advanced 4.69% on November 5, 2026, closing at ₹1,785.00 after moving between an intraday low of ₹1,696.00 and a high of ₹1,796.00, which also marked a new 52-week high.
- Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, posting a record quarterly revenue of ₹10,263 crore and a net profit of ₹1,124 crore, alongside an EBITDA of ₹2,156 crore. The Board also declared an interim dividend of ₹7.00 per equity share of Re. 1, fixing November 11, 2026, as the record date.
- Trading volume was 3.51 times the 20-day average daily volume.
Why is Aurobindo Pharma share price rising on 5 November 2026?
Aurobindo Pharma Limited shares advanced 4.69% on November 5, 2026, closing at ₹1,785.00 after moving between an intraday low of ₹1,696.00 and a high of ₹1,796.00, which also marked a new 52-week high.
The broader market and sector also experienced positive momentum during the session, with the Nifty benchmark gaining 2.40% and the Nifty Pharma sector index rising 1.00%. Aurobindo Pharma outperformed both benchmarks, building on a strong recent trajectory that includes a 5-day return of 7.54% and a 20-day return of 6.12%.
Company filings from November 4, 2026 outline multiple material corporate updates, including record second-quarter financial results for FY27 with revenue touching ₹10,263 crore and a net profit of ₹1,124 crore, alongside an interim dividend of ₹7.00 per share with a record date of November 11, 2026. Additional announcements covered internal restructuring, such as the proposed merger of Auroactive Pharma Private Limited into Apitoria Pharma Private Limited and the transfer of ownership of Auro Pharma LLC in Russia.
30.99 lakh shares traded by 5 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 8.83 lakh shares (3.51 times). The five-day average daily volume was 11.13 lakh shares. Separately, the NSE report for 5 November 2026 showed 10.75 lakh shares delivered, representing 34.68% of that day’s traded volume. The same report recorded 109,754 trades.
The stock's 4.69% advance and heavy volume—3.51 times its 20-day average—coincided closely with the release of record Q2 FY27 financial results, strong profitability metrics, and a ₹7.00 interim dividend announcement.
Latest Company Developments
Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, posting a record quarterly revenue of ₹10,263 crore and a net profit of ₹1,124 crore, alongside an EBITDA of ₹2,156 crore. The Board also declared an interim dividend of ₹7.00 per equity share of Re. 1, fixing November 11, 2026, as the record date.
Demonstrates robust operational performance and strong cash generation across key international markets, directly impacting investor valuation.
The Board of Directors approved a scheme of amalgamation for the merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited, both wholly owned subsidiaries engaged in active pharmaceutical ingredients. The transaction aims to consolidate API businesses, improve operational efficiencies, and streamline the group's corporate structure.
Enhances internal operational efficiency and capacity utilization within the group's manufacturing framework.
The company approved the transfer of ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited for a cash consideration of approximately ₹29 crore. Both entities are wholly owned subsidiaries of Aurobindo Pharma.
Represents an internal corporate reorganization to streamline holdings of the Russian subsidiary.
Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20 NDTV Profit
Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high Moneycontrol.com
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.
The filing reported 44 MF/UTI holders.
Research & Brokerage Views
Maintained a positive stance on Aurobindo Pharma supported by solid operational growth and expanding market share.
What to Watch Next
- Execution of the proposed merger between Auroactive Pharma and Apitoria Pharma through the NCLT process.
- Developments regarding the record date of November 11, 2026 for the interim dividend payout.
- Sustained volume participation relative to the 20-day average volume of 3.51x.
- Integration progress and performance of recent US market product launches and acquisitions.
Other Dated Coverage
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 2.43% | 23 October 2026 — 23 October 2026
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 1.41% | 22 October 2026 — 22 October 2026
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 3.08% | 19 October 2026 — 19 October 2026
More Aurobindo Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Aurobindo Pharma company news?
Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, posting a record quarterly revenue of ₹10,263 crore and a net profit of ₹1,124 crore, alongside an EBITDA of ₹2,156 crore. The Board also declared an interim dividend of ₹7.00 per equity share of Re. 1, fixing November 11, 2026, as the record date.
How strong was Aurobindo Pharma’s trading volume?
30.99 lakh shares traded, 3.51 times the 20-day average daily volume. The price and volume data are dated 5 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
SEBI Registration No.: INH000008172 · BSE Enlistment No.: 5430
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.